Patents by Inventor Paul S. Changelian

Paul S. Changelian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrolo[2,3-d]pyrimidine compounds
    Patent number: 7569569
    Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type 1 diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
    Type: Grant
    Filed: August 13, 2003
    Date of Patent: August 4, 2009
    Assignee: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Matthew F. Brown, Paul S. Changelian
  • Method of treatment of transplant rejection
    Patent number: 7250420
    Abstract: A method of treating or preventing chronic organ transplant rejection comprising administering a compound of the formula wherein R1, R2 and R3 are as defined above.
    Type: Grant
    Filed: November 24, 2003
    Date of Patent: July 31, 2007
    Assignee: Pfizer Inc.
    Inventor: Paul S. Changelian
  • Pyrrolo [2,3-D] pyrimidine compounds
    Patent number: 6890929
    Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: May 10, 2005
    Assignee: Pfizer, Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Matthew F. Brown, Paul S. Changelian
  • Method of treatment of transplant rejection
    Publication number: 20040116449
    Abstract: A method of treating or preventing chronic organ transplant rejection comprising administering a compound of the formula 1
    Type: Application
    Filed: November 24, 2003
    Publication date: June 17, 2004
    Applicant: Pfizer Inc
    Inventor: Paul S. Changelian
  • Pyrrolo[2,3-d]pyrimidine compounds
    Publication number: 20040058922
    Abstract: A compound of the formula 1
    Type: Application
    Filed: August 13, 2003
    Publication date: March 25, 2004
    Applicant: Pfizer inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Matthew F. Brown, Paul S. Changelian
  • Pyrrolo [2,3-D] pyrimidine compounds
    Publication number: 20030212273
    Abstract: A compound of the formula 1
    Type: Application
    Filed: May 20, 2003
    Publication date: November 13, 2003
    Applicant: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Matthew F. Brown, Paul S. Changelian
  • Monocyclic-7H-pyrrolo[2,3-d]pyrimidine compounds, compositions, and methods of use
    Patent number: 6635762
    Abstract: Novel pyrrolo[2,3-d]pyrimidine compounds useful as inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 as well as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases are described.
    Type: Grant
    Filed: June 17, 1999
    Date of Patent: October 21, 2003
    Assignee: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Matthew F. Brown, Paul S. Changelian
  • Pyrrolo[2,3-d]pyrimidine compounds
    Patent number: 6610847
    Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
    Type: Grant
    Filed: September 19, 2001
    Date of Patent: August 26, 2003
    Assignee: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Matthew F. Brown, Paul S. Changelian
  • Pyrrolo[2,3-d]pyrimidine compounds
    Publication number: 20020019526
    Abstract: A compound of the formula 1
    Type: Application
    Filed: September 19, 2001
    Publication date: February 14, 2002
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Matthew F. Brown, Paul S. Changelian